Compare Packaging Corporation of America (PKG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Packaging Corporation of America vs Spyre Therapeutics Inc. Common Stock — how do they compare? Packaging Corporation of America trades at $229.41 (market cap $20.64B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Packaging Corporation of America is far larger — about 2.7× Spyre Therapeutics Inc. Common Stock's market cap, and Packaging Corporation of America pays a 2.59% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Packaging Corporation of America for 47 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PKG | SYRE | |
|---|---|---|
Market Cap | $20.64B | $7.52B |
Volume | 529,375 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $257.43 | $108.92 |
52-Week Low | $191.68 | $22.18 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $24.45B | $6.52B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Packaging Corporation of America (PKG) trades at $231.65, up 1.68% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, while revenue is projected to grow to $9.5B in 2026. Analyst consensus is a 'Hold' with a $272.43 price target, and the stock offers a $1.50 quarterly dividend. Recent news highlights institutional investments and upcoming Q3 earnings discussion.
PKG presents a cautious outlook with steady revenue growth offset by margin pressures, as net income is expected to decline to $692M in 2026. The primary opportunity lies in the consensus price target suggesting ~18% upside, but risks include rising costs, competitive pressures, and bearish technical trends. Investors should weigh the dividend yield against earnings volatility and valuation multiples above sector averages.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
